Open AccessAntimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program
Author(s) -
Lynn-Yao Lin,
Dmitri Debabov,
William Chang,
Gregory G. Stone,
Todd Riccobene
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01985-21
Subject(s) - ceftazidime/avibactam , meropenem , pseudomonas aeruginosa , microbiology and biotechnology , klebsiella pneumoniae , broth microdilution , ceftazidime , antimicrobial , biology , avibactam , minimum inhibitory concentration , antibiotic resistance , antibiotics , bacteria , escherichia coli , biochemistry , genetics , gene
In vitro activities of ceftazidime-avibactam (CAZ-AVI) and key comparators against AmpC-overproducingEnterobacterales andP. aeruginosa isolates from four Phase 3 clinical trials and against OXA-48-producingEnterobacterales with multiple resistance mechanisms from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, were evaluated. Susceptibility to CAZ-AVI and comparators was determined by reference broth microdilution methods.